# A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302

> **NCT02468570** · — · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 9 (actual)

## Conditions studied

- Phenylketonuria

## Interventions

- **OTHER:** Administration of CANTAB and Subject Global Assessment

## Key facts

- **NCT ID:** NCT02468570
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-05
- **Primary completion:** 2017-02-01
- **Final completion:** 2017-02-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02468570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02468570, "A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02468570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*